Could a Two-Drug shot beat the standard for shoulder pain?
NCT ID NCT06376981
First seen Jun 25, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether adding hyaluronic acid to a standard corticosteroid injection works better for shoulder tendonitis pain than the steroid alone. About 132 adults with confirmed supraspinatus tendinopathy will receive either the combo or a placebo injection. Pain levels are checked at 1, 3, and 6 months to see which approach provides more relief.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- hyaluronic acid and corticosteroid injection
- What this could lead to
- If it works, this could offer a more effective injection for shoulder tendonitis pain, reducing the need for stronger treatments.
- What could go wrong
- This is a mid-stage trial with only 132 participants, so results may not apply to everyone. Adding hyaluronic acid may not provide extra benefit over the standard steroid shot.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 3
Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.
- Participants
-
About 132 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Sep 2024
- Expected to finish
-
Mar 2030
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 65 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Active patient aged between 18 and 65; * Patient suffering from pain compatible with supraspinatus tendinopathy for at least 2 months; * Patient with simple tendinopathy or partial tendon rupture; * Patient with tendinopathy confirmed by ultrasound or MRI; * Patient with an active pain visual analog scale ≥ 4 for more than 6 weeks; * Patient with an active pain visual analog scale ≥ 4 on the day of inclusion; * Patient failing medical treatment (rest, analgesics, NSAIDs, physiotherapy); * Patient able to follow the protocol and having given oral informed consent to take part in the research; * Patient affiliated to the social security system or entitled person; Exclusion Criteria: * Patient suffering from a transfixing tendon rupture; * Patients suffering from post-traumatic tendon rupture; * Patients suffering from calcific tendinopathy (calcification \> 5 mm); * Patients with associated glenohumeral osteoarthritis; * Patients with associated symptomatic acromioclavicular osteoarthritis; * Patients with shoulder pain for reasons other than tendinopathy (capsulitis, chronic inflammatory rheumatism, fibromyalgia, amyloidosis); * Patients who have had a subacromial infiltration in the previous 6 months; * Patients with a known allergy to one of the products including their excipients (methyl parahydroxybenzoate, propyl parahydroxybenzoate, benzyl alcohol); * Patients with a known allergy to lidocaine; * Patients with a local or generalised infection, or suspected infection; * Patients with severe coagulation disorders or taking anticoagulants; * Patients with severe and/or uncontrolled hypertension \> 160/100 mmHg; * Patients with unbalanced diabetes (last HbA1c \> 8.5%); * Patients with a history of addiction to psychoactive substances; * Patient participating in another clinical research protocol with an impact on the research objectives; * Patient already randomised in the study; * Patient who is pregnant, parturient, breastfeeding or able to procreate without effective contraception\* in the month prior to inclusion and up to 15 days after infiltration; * Patients under guardianship, curators or deprived of liberty; * Patient under a mandate for future protection activated ; * Patient under family guardianship ; * Patient under court protection ;
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Shoulder tendinitis are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
2 sites. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
CHD Vendée
RECRUITINGLa Roche-sur-Yon, France
-
CHU Nantes
RECRUITINGNantes, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could treadmill workouts be the key to soothing diabetic shoulder pain?
- Which Non-Surgical treatment eases shoulder calcium pain best?
- Laser vs shock wave: which zaps shoulder pain better?
- Gentle shoulder moves could ease rotator cuff pain without surgery
- Could adding cupping to acupuncture double shoulder pain relief?
- Zap away shoulder pain? new combo therapy put to the test